Treatment-Related Toxicities During Anti-GD2 Immunotherapy in High-Risk Neuroblastoma Patients

Treatment-Related Toxicities During Anti-GD2 Immunotherapy in High-Risk Neuroblastoma Patients

The introduction of immunotherapy using an anti-GD2 antibody (dinutuximab, ch14.18) has significantly improved survival rates for high-risk neuroblastoma patients. However, this improvement in survival is accompanied by a substantial immunotherapy-related toxicity burden. The primary objective of th...

Full description

Bibliographic Details
Main Authors: Thomas Blom, Roosmarijn Lurvink, Leonie Aleven, Maarten Mensink, Tom Wolfs, Miranda Dierselhuis, Natasha van Eijkelenburg, Kathelijne Kraal, Max van Noesel, Martine van Grotel, Godelieve Tytgat
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-02-01
Series:Frontiers in Oncology
Subjects:
neuroblastoma
immunotherapy
dinutuximab
ch14.18
anti-GD2 antibody
safety
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2020.601076/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2020.601076/full

Similar Items